About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage biotechnology company developing novel targeted therapies for inflammation, autoimmune diseases and cancer.

Noxopharm’s proprietary Sofra™ platform is designed to regulate innate immune signalling with greater precision. Its lead clinical asset, SOF-SKN™, is a topical therapy initially being developed for cutaneous lupus erythematosus, with Phase I completed and further clinical development progressing.

Beyond SOF-SKN, the Sofra platform supports a broader pipeline of internal and externally collaborated programs across inflammatory and autoimmune diseases, RNA therapeutics and oncology.

A core strength at all levels of the company is a focus on external collaborations, whether with research institutions and academia, suppliers or industry partners both in Australia and overseas. These relationships enable Noxopharm and its network to efficiently develop new proprietary assets that have demonstrable commercial potential.